BCG Vaccine Market by Age Group, Application, Distribution Channel, and By Region

The global BCG vaccine market size was estimated to be USD 104.6 million in 2023 and is expected to reach USD 187.9 million by 2034 with a CAGR of 5.47% during the forecast period 2024-2034. The high prevalence of tuberculosis, expansion of vaccination programs, growing awareness of off-label uses, technological advancements and product development, government and international support, and collaborations and partnerships will drive the market growth.

The primary cause is the ongoing global TB epidemic. The WHO predicted that there would be 10 million additional cases in 2020, underscoring the need for BCG immunization in prevention. Since TB mostly affects people in their prime working years, it is a serious public health and economic problem. For instance, in October 2023, Merck & Co., Inc. partnered with PATH and the Bill & Melinda Gates Foundation to create BCG vaccinations that are thermostable.

By age group, the pediatrics segment accounted for the highest revenue-grossing segment in the global BCG vaccine market in 2023 owing to the prioritization of childhood immunization programs, increased awareness about the importance of early vaccination, and widespread government initiatives aimed at protecting infants and young children from infectious diseases, particularly tuberculosis. For instance, Sanofi Pasteur announced in May 2023 that its thermostable BCG vaccine candidate has completed its Phase I clinical study. Additionally, the adult segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising recognition of the BCG vaccine's potential in non-tuberculosis applications, including its exploration for immunotherapy in various adult-onset diseases, such as certain forms of cancer.

By application, the tuberculosis segment accounted for the highest revenue-grossing segment in the global BCG vaccine market in 2023 owing to the persistent global burden of tuberculosis, especially in high-burden regions and developing countries. For instance, the Japan BCG Laboratory expanded its market reach in July 2023 when it received WHO prequalification for its freeze-dried BCG vaccine. Additionally, the bladder cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of the BCG vaccine's efficacy in the treatment and prevention of superficial bladder cancer.

By distribution channel, the hospital's segment accounted for the highest revenue-grossing segment in the global BCG vaccine market in 2023 owing to the central role hospitals play as key healthcare providers, facilitating widespread vaccine administration, and immunization programs. For instance, Statens Serum Institute introduced a new, improved version of its freeze-dried BCG vaccination with increased durability in March 2023. Additionally, the clinics and other channels segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend towards decentralized healthcare delivery, rising awareness about preventive healthcare in local communities, and the expanding role of specialized clinics and alternative healthcare channels in vaccination programs.

North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, robust immunization programs, and a high level of awareness regarding the importance of vaccination. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing population, rising healthcare awareness, and the implementation of extensive vaccination programs. For instance, the Serum Institute of India received WHO prequalification for their liquid BCG vaccine in February 2023, allowing UN procurement agencies to obtain the vaccine.

This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.

Report Scope:

• Base Year: 2023
• Forecast Period: 2024-2034
• Study Coverage
• Market Forecast by Age Group, Application, and Distribution Channel
• Market Forecast for 5 Regions and 17+ Countries
• North America (U.S. and Canada)
• Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
• Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
• MEA (South Africa, GCC, Rest of MEA)
• Exhaustive Company Profiles of the Top 10+ Major Market Players
• 20% Free Customization Available to Meet Your Exact Requirement.

Segmentation: BCG Vaccine Market Report 2023 - 2034

BCG Vaccine Market Analysis & Forecast by Age Group 2023 - 2034 (Revenue USD Mn)

• Pediatrics
• Adults

BCG Vaccine Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Mn)

• Tuberculosis
• Bladder Cancer

BCG Vaccine Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Mn)

• Hospitals
• Clinics
• Others

BCG Vaccine Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA